How tobacco protects you against the flu.

German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg Germany.
Tobacco control (Impact Factor: 5.93). 06/2008; 17(3):215-6. DOI: 10.1136/tc.2007.024521
Source: PubMed


Under the heading "How tobacco protects you against the flu", the German chemical industry portrays a tobacco grower in an idyllic tobacco plantation. Despite the recent ban of transnational tobacco advertising within the European Union, using tobacco to promote another industry and potential societal health benefits might indirectly promote the social acceptability of tobacco to social leaders. The tobacco control community should thus monitor the use of other industries as a new method to circumvent the tobacco advertising ban and to support the social acceptability of tobacco by associating it with potential health benefits.

1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: Corporate diversification allows for well-hidden financial ties between pharmaceutical and tobacco companies, which can cause a conflict of interest in the development and marketing of pharmaceutical products. In our investigation of tobacco company documents released and posted on the Internet as a result of the Master Settlement Agreement, we have found that these financial ties have fostered both competition and collaboration between the tobacco and pharmaceutical industries. We present 3 case studies. One shows how tobacco companies pressured pharmaceutical companies to scale back their smoking cessation educational materials that accompanied Nicorette. The second shows how they restricted to whom the pharmaceutical company could market its transdermal nicotine patch. In the third case, we show how subsidiary tobacco and pharmaceutical companies of a parent company collaborated in the production of a nicotine-release gum. Thus, because tobacco cessation product marketing has been altered as a result of these financial conflicts, disclosure would serve the interest of public health.
    JAMA The Journal of the American Medical Association 09/2002; 288(6):738-44. DOI:10.1001/jama.288.6.738 · 35.29 Impact Factor